FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

Holzkirchen, Germany, October 31, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news